What is B. Riley's Estimate for TG Therapeutics Q2 Earnings?

TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) - Analysts at B. Riley increased their Q2 2025 earnings estimates for shares of TG Therapeutics in a research report issued to clients and investors on Monday, May 5th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will earn $0.30 per share for the quarter, up from their previous forecast of $0.27. The consensus estimate for TG Therapeutics' current full-year earnings is $0.08 per share. B. Riley also issued estimates for TG Therapeutics' Q4 2025 earnings at $0.34 EPS, FY2025 earnings at $1.14 EPS and FY2029 earnings at $4.58 EPS.

A number of other research firms also recently commented on TGTX. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and issued a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $40.80.

TG Therapeutics Price Performance

TG Therapeutics stock traded up $0.41 during midday trading on Wednesday, reaching $34.05. The company had a trading volume of 1,055,316 shares, compared to its average volume of 3,014,735. The company has a market capitalization of $5.41 billion, a P/E ratio of -341.05 and a beta of 2.21. TG Therapeutics has a 12-month low of $15.16 and a 12-month high of $46.48. The firm's fifty day simple moving average is $38.90 and its 200-day simple moving average is $33.70. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). The firm had revenue of $120.86 million for the quarter, compared to analysts' expectations of $117.07 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The company's revenue was up 90.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.07) earnings per share.

Institutional Investors Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in TG Therapeutics by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 15,596,480 shares of the biopharmaceutical company's stock valued at $469,454,000 after acquiring an additional 209,190 shares during the period. Soleus Capital Management L.P. lifted its holdings in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company's stock valued at $80,705,000 after acquiring an additional 146,702 shares during the period. Clearbridge Investments LLC acquired a new stake in TG Therapeutics in the fourth quarter valued at $55,237,000. Northern Trust Corp lifted its holdings in TG Therapeutics by 8.6% in the fourth quarter. Northern Trust Corp now owns 1,532,929 shares of the biopharmaceutical company's stock valued at $46,141,000 after acquiring an additional 120,785 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in shares of TG Therapeutics by 7.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,269,513 shares of the biopharmaceutical company's stock valued at $38,212,000 after buying an additional 84,904 shares in the last quarter. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.